Soumya D Chakravarty

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 46

Top Topics

Rheumatoid Arthritis

Placebo Controlled

Top Venues

Clinical rheumatology

ACR open rheumatology

Arthritis & rheumatology (Hoboken, N.J.)

This page only lists publications with an associated author ORCID identifier.

Publications

Phillip J Mease, Alexis Ogdie, John Tesser, Natalie J Shiff, Ruizhi Sophia Zhao, Soumya D Chakravarty, Michael Kelleman, Rhiannon Dodge, Robert R McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph F Merola
Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. ACR open rheumatology 6 (5) (2024)
Stefan Siebert, Laura C Coates, Larissa Valor-Méndez, Siba P Raychaudhuri, Warner Chen, Sheng Gao, Loqmane Seridi, Soumya D Chakravarty, May Shawi, Frederic Lavie, Mohamed Sharaf, Miriam Zimmermann, Alexa P Kollmeier, Xie L Xu, Proton Rahman, Phillip J Mease, Atul A Deodhar
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.) 76 (6) (2024)
Jessica A Walsh, Iris Lin, Ruizhi Zhao, Natalie J Shiff, Laura Morrison, Bruno Emond, Louise H Yu, Samuel Schwartzbein, Patrick Lefebvre, Dominic Pilon, Soumya D Chakravarty, Philip Mease
Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors. Drugs - real world outcomes 11 (3) (2024)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, Diamant Thaҫi, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph Frank Merola, Iain B McInnes, Atul A Deodhar
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical rheumatology (2024)
Xenofon Baraliakos, Dafna D Gladman, Soumya D Chakravarty, Cinty Gong, May Shawi, Emmanouil Rampakakis, Kishimoto Mitsumasa, Enrique Roberto Soriano, Phillip J Mease
BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studies. Rheumatology advances in practice 8 (2) (2024)
Jessica A Walsh, Iris Lin, Ruizhi Zhao, Natalie J Shiff, Laura Morrison, Bruno Emond, Louise H Yu, Samuel Schwartzbein, Patrick Lefebvre, Dominic Pilon, Soumya D Chakravarty, Philip Mease
Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors. Drugs - real world outcomes 11 (3) (2024)
Jessica A Walsh, Iris Lin, Ruizhi Zhao, Natalie J Shiff, Laura Morrison, Bruno Emond, Louise H Yu, Samuel Schwartzbein, Patrick Lefebvre, Dominic Pilon, Soumya D Chakravarty, Philip Mease
Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors. Drugs - real world outcomes (2024)
Stefan Siebert, Laura C Coates, Larissa Valor-Méndez, Siba P Raychaudhuri, Warner Chen, Sheng Gao, Loqmane Seridi, Soumya D Chakravarty, May Shawi, Frederic Lavie, Mohamed Sharaf, Miriam Zimmermann, Alexa P Kollmeier, Xie L Xu, Proton Rahman, Phillip J Mease, Atul A Deodhar
Modulation of IL-23 Signaling With Guselkumab in Biologic-Naïve Patients Versus TNF Inhibitor-Inadequate Responders With Active Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.) (2024)
Phillip J Mease, Alexis Ogdie, John Tesser, Natalie J Shiff, Ruizhi Sophia Zhao, Soumya D Chakravarty, Michael Kelleman, Rhiannon Dodge, Robert R McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph F Merola
Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. ACR open rheumatology (2024)
Jessica A Walsh, Iris Lin, Ruizhi Zhao, Natalie J Shiff, Laura Morrison, Bruno Emond, Louise H Yu, Samuel Schwartzbein, Patrick Lefebvre, Dominic Pilon, Soumya D Chakravarty, Philip Mease
Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor Inhibitors. Drugs - real world outcomes 11 (3) (2024)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, Diamant Thaҫi, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph Frank Merola, Iain B McInnes, Atul A Deodhar
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical rheumatology 43 (8) (2024)
Stefan Siebert, Laura C Coates, Larissa Valor-Méndez, Siba P Raychaudhuri, Warner Chen, Sheng Gao, Loqmane Seridi, Soumya D Chakravarty, May Shawi, Frederic Lavie, Mohamed Sharaf, Miriam Zimmermann, Alexa P Kollmeier, Xie L Xu, Proton Rahman, Phillip J Mease, Atul A Deodhar
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.) 76 (6) (2024)
Xenofon Baraliakos, Dafna D Gladman, Soumya D Chakravarty, Cinty Gong, May Shawi, Emmanouil Rampakakis, Kishimoto Mitsumasa, Enrique Roberto Soriano, Phillip J Mease
BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studies. Rheumatology advances in practice 8 (2) (2024)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, Diamant Thaҫi, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph Frank Merola, Iain B McInnes, Atul A Deodhar
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical rheumatology 43 (8) (2024)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, Diamant Thaҫi, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph Frank Merola, Iain B McInnes, Atul A Deodhar
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical rheumatology 43 (8) (2024)
Phillip J Mease, Alexis Ogdie, John Tesser, Natalie J Shiff, Ruizhi Sophia Zhao, Soumya D Chakravarty, Michael Kelleman, Rhiannon Dodge, Robert R McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph F Merola
Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. ACR open rheumatology 6 (5) (2024)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, Diamant Thaҫi, Soumya D Chakravarty, Emmanouil Rampakakis, May Shawi, Elena Schiopu, Joseph Frank Merola, Iain B McInnes, Atul A Deodhar
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clinical rheumatology 43 (8) (2024)
Phillip J Mease, Alexis Ogdie, John Tesser, Natalie J Shiff, Ruizhi Sophia Zhao, Soumya D Chakravarty, Michael Kelleman, Rhiannon Dodge, Robert R McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph F Merola
Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. ACR open rheumatology 6 (5) (2024)
Stefan Siebert, Laura C Coates, Larissa Valor-Méndez, Siba P Raychaudhuri, Warner Chen, Sheng Gao, Loqmane Seridi, Soumya D Chakravarty, May Shawi, Frederic Lavie, Mohamed Sharaf, Miriam Zimmermann, Alexa P Kollmeier, Xie L Xu, Proton Rahman, Phillip J Mease, Atul A Deodhar
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.) (2024)
Bruce E Strober, Laura C Coates, Mark G Lebwohl, Atul Deodhar, Evan Leibowitz, Katelyn Rowland, Alexa P Kollmeier, Megan Miller, Yanli Wang, Shu Li, Soumya D Chakravarty, Daphne Chan, May Shawi, Ya-Wen Yang, Diamant Thaҫi, Proton Rahman
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis. Drug safety (2023)
Dennis McGonagle, Iain B McInnes, Atul A Deodhar, Larissa Valor-Méndez, May Shawi, Soumya D Chakravarty, Alexa P Kollmeier, Xie L Xu, Shihong Sheng, Stephen Xu, Christopher T Ritchlin, Proton Rahman, Phillip J Mease
Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies. ACR open rheumatology (2023)
Alice B Gottlieb, Iain B McInnes, Proton Rahman, Alexa P Kollmeier, Xie L Xu, Yusang Jiang, Shihong Sheng, May Shawi, Soumya D Chakravarty, Frederic Lavie, Phillip J Mease
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis. RMD open 9 (1) (2023)
Alice B Gottlieb, Iain B McInnes, Proton Rahman, Alexa P Kollmeier, Xie L Xu, Yusang Jiang, Shihong Sheng, May Shawi, Soumya D Chakravarty, Frederic Lavie, Phillip J Mease
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis. RMD open 9 (1) (2023)
Phillip J Mease, Philip S Helliwell, Diamant Thaҫi, Natalie J Shiff, Iris Lin, Soumya D Chakravarty, Michael S Kelleman, Rhiannon Dodge, Robert R McLean, Aaron Broadwell, Arthur Kavanaugh, Joseph Frank Merola
Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Rheumatology and therapy (2023)
Phillip J Mease, Alice B Gottlieb, Philip S Helliwell, Iain B McInnes, Soumya D Chakravarty, Emmanouil Rampakakis, Alexa P Kollmeier, Xie L Xu, May Shawi, Frederic Lavie, Kishimoto Mitsumasa, Proton Rahman
Earlier clinical response predicts low rates of radiographic progression in biologic-naïve patients with active psoriatic arthritis receiving guselkumab treatment. Clinical rheumatology (2023)
Laure Gossec, Elke Theander, Soumya D Chakravarty, Paul Bergmans, Frederic Lavie, Wim Noël, Mohamed Sharaf, Stefan Siebert, Josef S Smolen
Response to treatment in psoriatic arthritis, the effect of age: analysis of patients receiving ustekinumab in the PsABio real-world study. Arthritis research & therapy 25 (1) (2023)
Phillip J Mease, Dafna D Gladman, Denis Poddubnyy, Soumya D Chakravarty, May Shawi, Alexa P Kollmeier, Xie L Xu, Stephen Xu, Atul Deodhar, Xenofon Baraliakos
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study. Rheumatology and therapy (2023)
Arthur Kavanaugh, Xenofon Baraliakos, Sheng Gao, Warner Chen, Kristen M Sweet, Soumya D Chakravarty, Qingxuan Song, May Shawi, Proton Rahman
Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials. Advances in therapy (2023)
Ana Maria Orbai, Soumya D Chakravarty, Yin You, May Shawi, Ya-Wen Yang, Joseph Frank Merola
Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis. Dermatology and therapy (2023)
Dafna D Gladman, Phillip J Mease, Paul Bird, Enrique Roberto Soriano, Soumya D Chakravarty, May Shawi, Frederic Lavie, Cinty Gong, Evan Leibowitz, Denis Poddubnyy, Lai Shan Tam, Philip S Helliwell, Arthur Kavanaugh, Atul A Deodhar, Mikkel Østergaard, Xenofon Baraliakos
Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?' by Braun and Landewé. Annals of the rheumatic diseases (2022)
Dafna D Gladman, Philip J Mease, Paul Bird, Enrique Roberto Soriano, Soumya D Chakravarty, May Shawi, Stephen Xu, Sean T Quinn, Cinty Gong, Evan Leibowitz, Denis Poddubnyy, Lai-Shan Tam, Philip S Helliwell, Arthur Kavanaugh, Atul Deodhar, Mikkel Østergaard, Xenofon Baraliakos
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial. Trials 23 (1) (2022)
Phillip J Mease, Soumya D Chakravarty, Robert R McLean, Taylor Blachley, Toana Kawashima, Iris Lin, Arthur Kavanaugh, Alexis Ogdie
Treatment Responses in Patients With Psoriatic Arthritis Axial Disease According to Human Leukocyte Antigen-B27 Status: An Analysis From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. ACR open rheumatology 4 (5) (2022)
Rebecca H Haberman, Katrina A MacFarlane, Sydney Catron, Jonathan Samuels, Rebecca B Blank, Michael Toprover, Zakwan Uddin, Jiyuan Hu, Rochelle Castillo, Cinty Gong, Kun Qian, Vincent Piguet, Francisco Tausk, Jensen Yeung, Andrea L Neimann, Wayne Gulliver, Ralf G Thiele, Joseph F Merola, Alexis Ogdie, Proton Rahman, Soumya D Chakravarty, Lihi Eder, Christopher T Ritchlin, Jose U Scher
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ open 12 (12) (2022)
Rebecca H Haberman, Katrina A MacFarlane, Sydney Catron, Jonathan Samuels, Rebecca B Blank, Michael Toprover, Zakwan Uddin, Jiyuan Hu, Rochelle Castillo, Cinty Gong, Kun Qian, Vincent Piguet, Francisco Tausk, Jensen Yeung, Andrea L Neimann, Wayne Gulliver, Ralf G Thiele, Joseph F Merola, Alexis Ogdie, Proton Rahman, Soumya D Chakravarty, Lihi Eder, Christopher T Ritchlin, Jose U Scher
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ open 12 (12) (2022)
Christopher T Ritchlin, Phillip J Mease, Wolf-Henning Boehncke, John Tesser, Elena Schiopu, Soumya D Chakravarty, Alexa P Kollmeier, Xie L Xu, May Shawi, Yusang Jiang, Shihong Sheng, Yanli Wang, Stephen Xu, Joseph F Merola, Iain B McInnes, Atul Deodhar
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies. RMD open 8 (1) (2022)
M Elaine Husni, Atul A Deodhar, Sergio Schwartzman, Soumya D Chakravarty, Elizabeth C Hsia, Jocelyn H Leu, Yiying Zhou, Kim H Lo, Arthur Kavanaugh
Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Arthritis research & therapy 24 (1) (2022)
Rebecca H Haberman, Katrina A MacFarlane, Sydney Catron, Jonathan Samuels, Rebecca B Blank, Michael Toprover, Zakwan Uddin, Jiyuan Hu, Rochelle Castillo, Cinty Gong, Kun Qian, Vincent Piguet, Francisco Tausk, Jensen Yeung, Andrea L Neimann, Wayne Gulliver, Ralf G Thiele, Joseph F Merola, Alexis Ogdie, Proton Rahman, Soumya D Chakravarty, Lihi Eder, Christopher T Ritchlin, Jose U Scher
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ open 12 (12) (2022)
Diamant Thaҫi, Iris Lin, Natalie J Shiff, Soumya D Chakravarty, Gabriela Schmajuk, Nevin Hammam, Sheetal Desai
Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry. Clinical rheumatology 41 (8) (2022)
Rebecca H Haberman, Katrina A MacFarlane, Sydney Catron, Jonathan Samuels, Rebecca B Blank, Michael Toprover, Zakwan Uddin, Jiyuan Hu, Rochelle Castillo, Cinty Gong, Kun Qian, Vincent Piguet, Francisco Tausk, Jensen Yeung, Andrea L Neimann, Wayne Gulliver, Ralf G Thiele, Joseph F Merola, Alexis Ogdie, Proton Rahman, Soumya D Chakravarty, Lihi Eder, Christopher T Ritchlin, Jose U Scher
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ open 12 (12) (2022)
Rebecca H Haberman, Katrina A MacFarlane, Sydney Catron, Jonathan Samuels, Rebecca B Blank, Michael Toprover, Zakwan Uddin, Jiyuan Hu, Rochelle Castillo, Cinty Gong, Kun Qian, Vincent Piguet, Francisco Tausk, Jensen Yeung, Andrea L Neimann, Wayne Gulliver, Ralf G Thiele, Joseph F Merola, Alexis Ogdie, Proton Rahman, Soumya D Chakravarty, Lihi Eder, Christopher T Ritchlin, Jose U Scher
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial. BMJ open 12 (12) (2022)
Phillip J Mease, Iain B McInnes, Lai Shan Tam, Kiefer Eaton, Steve Peterson, Agata Schubert, Soumya D Chakravarty, Anna Parackal, Chetan S Karyekar, Sandhya Nair, Wolf-Henning Boehncke, Christopher Ritchlin
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. Rheumatology (Oxford, England) 60 (5) (2021)
Iain B McInnes, Proton Rahman, Alice B Gottlieb, Elizabeth C Hsia, Alexa P Kollmeier, Xie L Xu, Yusang Jiang, Shihong Sheng, May Shawi, Soumya D Chakravarty, Désirée van der Heijde, Phillip J Mease
Long-term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.) (2021)
Christopher T Ritchlin, Philip S Helliwell, Wolf-Henning Boehncke, Enrique Roberto Soriano, Elizabeth C Hsia, Alexa P Kollmeier, Soumya D Chakravarty, Federico Zazzetti, Ramanand A Subramanian, Xie L Xu, Qing C Zuraw, Shihong Sheng, Yusang Jiang, Prasheen Agarwal, Bei Zhou, Yanli Zhuang, May Shawi, Chetan S Karyekar, Atul Deodhar
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced. RMD open 7 (1) (2021)
Philip S Helliwell, Jessica A Walsh, Soumya D Chakravarty, Steven Peterson, Kim Hung Lo, Lilianne Kim, Nan Li, Elizabeth C Hsia, Eric K H Chan, Arthur Kavanaugh, M Elaine Husni
The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial. Clinical rheumatology 40 (9) (2021)
Iain B McInnes, Proton Rahman, Alice B Gottlieb, Elizabeth C Hsia, Alexa P Kollmeier, Soumya D Chakravarty, Xie L Xu, Ramanand A Subramanian, Prasheen Agarwal, Shihong Sheng, Yusang Jiang, Bei Zhou, Yanli Zhuang, Désirée van der Heijde, Phillip J Mease
Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis. Arthritis & rheumatology (Hoboken, N.J.) 73 (4) (2021)
Phillip J Mease, M Elaine Husni, Soumya D Chakravarty, Shelly Kafka, Dennis Parenti, Lilianne Kim, Kim Hung Lo, Elizabeth C Hsia, Arthur Kavanaugh
Evaluation of Improvement in Skin and Nail Psoriasis in Bio-naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO-VIBRANT Study. ACR open rheumatology 2 (11) (2020)